We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Medifast Stock to Post Q2 Earnings: What Investors Should Know
Read MoreHide Full Article
Key Takeaways
Medifast likely continued to face pressure from GLP-1 adoption and fewer active earning coaches.
MED's lower sales volumes may have continued to weigh on gross profit and margin performance.
MED is likely to benefit from stronger coach productivity and ongoing cost structure improvements.
As Medifast, Inc. (MED - Free Report) prepares to unveil its second-quarter fiscal 2026 results on Aug. 03, after market close, investors are eager to see if the company can beat market expectations.
The Zacks Consensus Estimate for revenues is pegged at $78.4 million, implying a 25.8% decline from the prior year. Meanwhile, the consensus mark for earnings has moved from a loss of 68 cents to a loss of 67 cents per share in the past seven days. This indicates a substantial decline from the year-ago period’s earnings of 4 cents. MED has a trailing four-quarter negative earnings surprise of 635.6%, on average.
Medifast likely continued to face headwinds from the rapid adoption of GLP-1 medications, which have been reshaping the traditional weight-loss market. The company has previously indicated that this shift is reducing demand for conventional weight management programs, placing continued pressure on coach participation and overall business performance. These industry dynamics are likely to have remained a meaningful headwind during the to-be-reported quarter.
The decline in the number of active earning coaches might have created pressure on revenue trends. The company has previously attributed weaker sales performance to the contraction in its coach network, and this trend is likely to have continued to weigh on overall business performance in the second quarter.
Profitability also likely remained challenged as softer sales volumes continued to pressure gross profit and margins. Management had previously noted that lower revenue reduced the company's ability to leverage fixed costs efficiently, resulting in margin compression. These factors might have continued to weigh on earnings performance during the quarter.
However, Medifast is also likely to have benefited from continued improvements in coach productivity. Management had previously highlighted that this key leading indicator of future growth had reached its highest level in many years and was expected to maintain positive momentum. In addition, the company's ongoing cost structure realignment likely supported operating performance by improving efficiency, generating cost savings and preserving profitability, while allowing continued investment in long-term growth initiatives. These efforts might have helped mitigate some pressure from the challenging operating environment.
What the Zacks Model Says About MED
Our proven model predicts an earnings beat for MED this time. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat, which is the case here.
MED has an Earnings ESP of +2.26% and a Zacks Rank #3. You can uncover the best stocks to buy or sell before they are reported with our Earnings ESP Filter.
Other Stocks With Favorable Combination
Here are three other companies you may also want to consider, as our model shows that these too have the right combination of elements to post an earnings beat this season:
The Kraft Heinz Company (KHC - Free Report) currently has an Earnings ESP of +3.08% and a Zacks Rank of 2. The Zacks Consensus Estimate for second-quarter 2026 earnings per share is pegged at 53 cents, implying a 23.2% year-over-year decline. You can see the complete list of today’s Zacks #1 Rank stocks here.
The Zacks Consensus Estimate for quarterly revenues is pegged at $6.2 billion, which indicates a decrease of 3% from the figure reported in the prior-year quarter. KHC has a trailing four-quarter earnings surprise of 10.2%, on average.
US Foods Holding Corp. (USFD - Free Report) currently has an Earnings ESP of +1.10% and a Zacks Rank of 2. The Zacks Consensus Estimate for second-quarter fiscal 2026 earnings per share is pegged at $1.37, implying a 15.1% year-over-year decline.
The Zacks Consensus Estimate for quarterly revenues is pegged at $10.5 billion, which indicates growth of 3.8% from the figure reported in the prior-year quarter. USFD has a trailing four-quarter earnings surprise of 1.4%, on average.
Sysco Corporation (SYY - Free Report) currently has an Earnings ESP of +0.56% and a Zacks Rank of 3. The Zacks Consensus Estimate for fourth-quarter fiscal 2026 earnings per share is pegged at $1.51, implying a 2% year-over-year increase.
The Zacks Consensus Estimate for quarterly revenues is pegged at $21.9 billion, which indicates an increase of 3.7% from the figure reported in the prior-year quarter. SYY has a trailing four-quarter earnings surprise of 2.1%, on average.
View the Zacks #1 Rank List
Image: Bigstock
Medifast Stock to Post Q2 Earnings: What Investors Should Know
Key Takeaways
As Medifast, Inc. (MED - Free Report) prepares to unveil its second-quarter fiscal 2026 results on Aug. 03, after market close, investors are eager to see if the company can beat market expectations.
The Zacks Consensus Estimate for revenues is pegged at $78.4 million, implying a 25.8% decline from the prior year. Meanwhile, the consensus mark for earnings has moved from a loss of 68 cents to a loss of 67 cents per share in the past seven days. This indicates a substantial decline from the year-ago period’s earnings of 4 cents. MED has a trailing four-quarter negative earnings surprise of 635.6%, on average.
MEDIFAST INC Price, Consensus and EPS Surprise
MEDIFAST INC price-consensus-eps-surprise-chart | MEDIFAST INC Quote
Key Factors to Note for MED's Q2 Earnings
Medifast likely continued to face headwinds from the rapid adoption of GLP-1 medications, which have been reshaping the traditional weight-loss market. The company has previously indicated that this shift is reducing demand for conventional weight management programs, placing continued pressure on coach participation and overall business performance. These industry dynamics are likely to have remained a meaningful headwind during the to-be-reported quarter.
The decline in the number of active earning coaches might have created pressure on revenue trends. The company has previously attributed weaker sales performance to the contraction in its coach network, and this trend is likely to have continued to weigh on overall business performance in the second quarter.
Profitability also likely remained challenged as softer sales volumes continued to pressure gross profit and margins. Management had previously noted that lower revenue reduced the company's ability to leverage fixed costs efficiently, resulting in margin compression. These factors might have continued to weigh on earnings performance during the quarter.
However, Medifast is also likely to have benefited from continued improvements in coach productivity. Management had previously highlighted that this key leading indicator of future growth had reached its highest level in many years and was expected to maintain positive momentum. In addition, the company's ongoing cost structure realignment likely supported operating performance by improving efficiency, generating cost savings and preserving profitability, while allowing continued investment in long-term growth initiatives. These efforts might have helped mitigate some pressure from the challenging operating environment.
What the Zacks Model Says About MED
Our proven model predicts an earnings beat for MED this time. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat, which is the case here.
MED has an Earnings ESP of +2.26% and a Zacks Rank #3. You can uncover the best stocks to buy or sell before they are reported with our Earnings ESP Filter.
Other Stocks With Favorable Combination
Here are three other companies you may also want to consider, as our model shows that these too have the right combination of elements to post an earnings beat this season:
The Kraft Heinz Company (KHC - Free Report) currently has an Earnings ESP of +3.08% and a Zacks Rank of 2. The Zacks Consensus Estimate for second-quarter 2026 earnings per share is pegged at 53 cents, implying a 23.2% year-over-year decline. You can see the complete list of today’s Zacks #1 Rank stocks here.
The Zacks Consensus Estimate for quarterly revenues is pegged at $6.2 billion, which indicates a decrease of 3% from the figure reported in the prior-year quarter. KHC has a trailing four-quarter earnings surprise of 10.2%, on average.
US Foods Holding Corp. (USFD - Free Report) currently has an Earnings ESP of +1.10% and a Zacks Rank of 2. The Zacks Consensus Estimate for second-quarter fiscal 2026 earnings per share is pegged at $1.37, implying a 15.1% year-over-year decline.
The Zacks Consensus Estimate for quarterly revenues is pegged at $10.5 billion, which indicates growth of 3.8% from the figure reported in the prior-year quarter. USFD has a trailing four-quarter earnings surprise of 1.4%, on average.
Sysco Corporation (SYY - Free Report) currently has an Earnings ESP of +0.56% and a Zacks Rank of 3. The Zacks Consensus Estimate for fourth-quarter fiscal 2026 earnings per share is pegged at $1.51, implying a 2% year-over-year increase.
The Zacks Consensus Estimate for quarterly revenues is pegged at $21.9 billion, which indicates an increase of 3.7% from the figure reported in the prior-year quarter. SYY has a trailing four-quarter earnings surprise of 2.1%, on average.